Biopharma & Life Sciences
Forte Biosciences Executive Compensation (FY25)
FBRX · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Paul Wagner | Latest say-on-pay support = May 29, 2026 |
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The Forte Biosciences brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Data as of October 20, 2026Latest filing (8-K): June 2, 2026
5 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
106 figures on this page: 102 cited to the filing that reported them, 4 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Paul Wagner: $1,674,458 → $7,358,587
Frequently asked questions
Answers drawn from the data on this page.
Who is Forte Biosciences' chief executive and what were they paid?
Paul Wagner was paid $7,358,587 in total compensation as Chairman, President and Chief Executive Officer for fiscal 2025. Compared with the $1,674,458 reported for fiscal 2024, Wagner's total was up.
What was Forte Biosciences' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 76.3% of votes cast for or against in favor at the meeting held May 29, 2026.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Paul Wagner Chairman, President and Chief Executive Officer | ◇ | ◇ | — | ◇ | — | — | — | ◇ |
Antony Riley Chief Financial Officer | ◇ | ◇ | — | ◇ | — | — | — | ◇ |
Hubert Chen Former President and Chief Scientific Officer | ◇ | ◇ | — | ◇ | — | — | — | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Paul Wagner Chairman, President and Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | — | ◇ |
Antony Riley Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | — | ◇ |
Hubert Chen Former President and Chief Scientific Officer | ◇ | — | ◇ | — | — | — | — | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Paul Wagner Chairman, President and Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | — | ◇ |
Antony Riley Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | — | ◇ |
Hubert Chen Former President and Chief Scientific Officer Departed during or after this year | ◇ | — | — | — | ◇ | — | — | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Paul Wagner Chairman, President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Antony Riley Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2023
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Antony Riley | RSU | — | — | — | ◇ | — | — | ◇ |
| Hubert Chen, M.D. | RSU | — | — | — | ◇ | — | — | ◇ |
| Paul Wagner, Ph.D. | RSU | — | — | — | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Paul Wagner | Option | ◇ | — | ◇ | 3/20/2035 |
| Option | ◇ | — | ◇ | 3/20/2034 | |
| RSU | ◇ | = | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/16/2032 | |
| Antony Riley | Option | ◇ | — | ◇ | 3/20/2035 |
| Option | ◇ | — | ◇ | 3/20/2034 | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | = | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Barbara K. Finck, M.D | — | — | ◇ | — | — | ◇ | ◇ |
Steven Kornfeld | ◇ | — | ◇ | — | — | — | ◇ |
Richard Vincent | ◇ | — | ◇ | — | — | — | ◇ |
Scott Brun, M.D | ◇ | — | ◇ | — | — | — | ◇ |
David Gryska | ◇ | — | ◇ | — | — | — | ◇ |
Stephen K. Doberstein, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Shiv Kapoor | ◇ | — | ◇ | — | — | — | ◇ |
Paul A. Wagner, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 29, 2026 | = | ◇ | ◇ | ◇ |
| 2022 | September 19, 2023 | = | ◇ | ◇ | ◇ |
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Paul Wagner (Chairman, President and Chief Executive Officer), FY2025 total compensation $7,358,587 (base salary $670,051) [exec_comp, SEC accession 0001193125-26-191515, filed 2026-04-29]What this page does not include
Everything above is a fact Forte Biosciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
106 figures on this page: 102 cited to the filing that reported them, 4 calculated from figures it prints.
102 cited to the filing
4 calculated from the filing
Documents cited
- 0001193125-26-253436Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001193125-26-191515Director Compensation · Outstanding Equity Awards at Fiscal 2025 Year-End
- 0001193125-25-107130
- 0001193125-24-188850
- 0001193125-23-238588Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Forte Biosciences executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/FBRX (accessed 2026).
Short form: data: Velarion
The Forte Biosciences brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
5 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Forte Biosciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}